Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Prostate-specific antigen screening for prostate cancer: benefits for patients with highly aggressive prostate cancer.

Jia HJ, Li Y, Wang JG, Zhang L, Zhang HT, Zhao XJ, Kuwahara M.

Asian J Androl. 2013 Mar;15(2):218-20. doi: 10.1038/aja.2012.130. Epub 2013 Jan 21.

2.

Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam.

Wever EM, Draisma G, Heijnsdijk EA, Roobol MJ, Boer R, Otto SJ, de Koning HJ.

J Natl Cancer Inst. 2010 Mar 3;102(5):352-5. doi: 10.1093/jnci/djp533. Epub 2010 Feb 8.

4.

Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.

Faria EF, Carvalhal GF, dos Reis RB, Tobias-Machado M, Vieira RA, Reis LO, Nogueira L, Machado RD, Freitas CH Jr, Magnabosco WJ, Mauad EC, Carvalho AL.

BJU Int. 2012 Dec;110(11 Pt B):E653-7. doi: 10.1111/j.1464-410X.2012.11398.x. Epub 2012 Aug 14.

5.

PSA-based screening for prostate cancer. Too many adverse effects.

[No authors listed]

Prescrire Int. 2012 Sep;21(130):215-7. Review.

PMID:
23016259
6.

Prostate cancer and prostate-specific antigen (PSA) screening in Austria.

Vutuc C, Schernhammer ES, Haidinger G, Waldhör T.

Wien Klin Wochenschr. 2005 Jul;117(13-14):457-61.

PMID:
16091872
7.

The prostate cancer pseudo-epidemic.

Adami HO.

Acta Oncol. 2010 Apr;49(3):298-304. doi: 10.3109/02841860903584945.

PMID:
20397765
8.

[Prostate cancer screening using prostate-specific antigen (PSA) determinations in plasma. National Academy of Medicine].

Bourel M, Ardaillou R; Académie nationale de médecine.

Bull Acad Natl Med. 2003;187(5):985-95. French.

PMID:
14979060
9.

[How to use PSA in 2009].

Ponholzer A, Stoiber F, Loidl W, Rauchenwald M, Schramek P, Madersbacher S.

Wien Med Wochenschr. 2009;159(21-22):515-20. doi: 10.1007/s10354-009-0718-0. Review. German.

PMID:
19997836
10.

[Clinical value of prostate specific antigen screening in early detection of prostate cancer].

Hua LX, Qiao D, Song NH, Feng NH, Yang J, Zhang JX, Chen JG, Zhang W, Sui YG, Wu HF.

Zhonghua Zhong Liu Za Zhi. 2009 Sep;31(9):705-9. Chinese.

PMID:
20021870
11.

Prostate cancer mortality in the Finnish randomized screening trial.

Kilpeläinen TP, Tammela TL, Malila N, Hakama M, Santti H, Määttänen L, Stenman UH, Kujala P, Auvinen A.

J Natl Cancer Inst. 2013 May 15;105(10):719-25. doi: 10.1093/jnci/djt038. Epub 2013 Mar 11.

PMID:
23479454
12.

[Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].

Jegu J, Tretarre B, Grosclaude P, Rebillard X, Bataille V, Malavaud B, Iborra F, Salama G, Rischmann P, Villers A.

Prog Urol. 2009 Jul;19(7):487-98. doi: 10.1016/j.purol.2009.03.001. Epub 2009 Apr 28. French.

PMID:
19559380
13.

[Advantages and risks of the use of prostate-specific antigen (PSA) in the health-care area No. 4 of Gijon (Asturias)].

Cepeda Piorno J, Rivas del Fresno M, Fuente Martín E, González García E, Muruamendiaraz Fernández V, Fernández Rodríguez E.

Arch Esp Urol. 2005 Jun;58(5):403-11. Spanish.

PMID:
16078781
14.

Screening for prostate cancer: updated experience from the Tyrol study.

Horninger W, Berger A, Pelzer A, Klocker H, Oberaigner W, Schönitzer D, Severi G, Robertson C, Boyle P, Bartsch G.

Can J Urol. 2005 Feb;12 Suppl 1:7-13; discussion 92-3.

PMID:
15780158
15.

[PSA related screening of prostate cancer. Panic or improvement?].

Fornara P, Jurczok A.

Aktuelle Urol. 2004 Feb;35(1):43-8. German.

PMID:
14997414
16.

Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.

Telesca D, Etzioni R, Gulati R.

Biometrics. 2008 Mar;64(1):10-9. Epub 2007 May 14.

PMID:
17501937
17.

Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force.

Lin K, Lipsitz R, Miller T, Janakiraman S; U.S. Preventive Services Task Force.

Ann Intern Med. 2008 Aug 5;149(3):192-9. Review.

PMID:
18678846
18.

Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination.

Schröder FH, Roobol-Bouts M, Vis AN, van der Kwast T, Kranse R.

Urology. 2001 Jan;57(1):83-90.

PMID:
11164149
19.

Prostate-specific antigen screening for prostate cancer in older men in the United States of America.

Black A, Berg CD.

Gerontology. 2012;58(4):331-6. doi: 10.1159/000334242. Epub 2012 Feb 16.

20.

Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit.

van Leeuwen PJ, Connolly D, Gavin A, Roobol MJ, Black A, Bangma CH, Schröder FH.

Eur J Cancer. 2010 Jan;46(2):377-83. doi: 10.1016/j.ejca.2009.09.008. Epub 2009 Oct 3.

PMID:
19804966

Supplemental Content

Support Center